Overview Dividends

(ENSG) The Ensign - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29358P1012

Nursing Care, Senior Living, Rehabilitative Services, Dialysis, Pharmacy

ENSG EPS (Earnings per Share)

EPS Growth (3Y CAGR): -55.94%
EPS Trend (3Y Correlation): -23.4%

ENSG Revenue

Revenue Growth (3Y CAGR): 18.49%
Revenue Trend (3Y Correlation): 99.2%

Description: ENSG The Ensign

The Ensign Group Inc (NASDAQ:ENSG) is a healthcare services provider operating in the US, focusing on skilled nursing, senior living, and rehabilitative care. The companys operations are divided into two main segments: Skilled Services, which provides a range of care services including short-term and long-term nursing care, specialty care, and standard services, and Standard Bearer, which leases post-acute care properties to healthcare operators.

With a presence in 16 states across the US, ENSG offers a broad spectrum of services, including senior living units, ancillary services such as digital x-ray and dialysis, and sub-acute services. The companys diversified service portfolio and geographic presence are key strengths, allowing it to capitalize on the growing demand for healthcare services.

From a financial perspective, ENSGs revenue growth, operating margins, and return on equity (ROE) are key performance indicators (KPIs) to monitor. With a ROE of 17.27%, the company demonstrates a reasonable return on shareholders equity. Additionally, the companys debt-to-equity ratio and interest coverage ratio are important metrics to assess its financial health and ability to service debt.

To further evaluate ENSGs investment potential, its essential to analyze its occupancy rates, average daily census, and revenue per patient day. These operational metrics can provide insights into the companys ability to maintain a stable and growing revenue stream. Furthermore, the companys ability to expand its services and increase its market share in the competitive healthcare landscape is crucial to its long-term success.

ENSG Stock Overview

Market Cap in USD	10,121m
Sub-Industry	Health Care Facilities
IPO / Inception	2007-11-09

ENSG Stock Ratings

Growth Rating	81.1%
Fundamental	73.1%
Dividend Rating	50.4%
Return 12m vs S&P 500	5.95%
Analyst Rating	4.50 of 5

ENSG Dividends

Dividend Yield 12m	0.14%
Yield on Cost 5y	0.44%
Annual Growth 5y	4.62%
Payout Consistency	98.6%
Payout Ratio	4.3%

ENSG Growth Ratios

Growth Correlation 3m	85.6%
Growth Correlation 12m	53.2%
Growth Correlation 5y	91.6%
CAGR 5y	29.21%
CAGR/Max DD 3y (Calmar Ratio)	1.24
CAGR/Mean DD 3y (Pain Ratio)	5.07
Sharpe Ratio 12m	0.80
Alpha	7.15
Beta	0.928
Volatility	21.35%
Current Volume	354.9k
Average Volume 20d	335.6k
Stop Loss	176.5 (-3%)
Signal	0.91

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (322.8m TTM) > 0 and > 6% of Revenue (6% = 276.9m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 1.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 6.75% (prev 9.69%; Δ -2.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 462.9m > Net Income 322.8m (YES >=105%, WARN >=100%)

Net Debt (1.68b) to EBITDA (525.7m) ratio: 3.19 <= 3.0 (WARN <= 3.5)

Current Ratio 1.41 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (58.6m) change vs 12m ago 1.02% (target <= -2.0% for YES)

Gross Margin 15.88% (prev 15.62%; Δ 0.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 98.53% (prev 89.41%; Δ 9.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 51.74 (EBITDA TTM 525.7m / Interest Expense TTM 8.34m) >= 6 (WARN >= 3)

Altman Z'' 2.65

(A) 0.06 = (Total Current Assets 1.07b - Total Current Liabilities 755.5m) / Total Assets 4.93b

(B) 0.32 = Retained Earnings (Balance) 1.58b / Total Assets 4.93b

(D) 0.54 = Book Value of Equity 1.58b / Total Liabilities 2.91b

Total Rating: 2.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 73.06

1. Piotroski 7.50pt = 2.50

2. FCF Yield 2.36% = 1.18

3. FCF Margin 6.00% = 1.50

4. Debt/Equity 1.01 = 2.01

5. Debt/Ebitda 3.19 = -2.01

6. ROIC - WACC (= 8.15)% = 10.18

7. RoE 17.15% = 1.43

8. Rev. Trend 99.18% = 7.44

9. EPS Trend -23.44% = -1.17

What is the price of ENSG shares?

As of October 18, 2025, the stock is trading at USD 182.04 with a total of 354,896 shares traded.
Over the past week, the price has changed by +3.82%, over one month by +9.74%, over three months by +31.15% and over the past year by +22.35%.

Is The Ensign a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, The Ensign (NASDAQ:ENSG) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 73.06 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ENSG is around 203.39 USD . This means that ENSG is currently undervalued and has a potential upside of +11.73% (Margin of Safety).

Is ENSG a buy, sell or hold?

The Ensign has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ENSG.

Strong Buy: 4
Buy: 1
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ENSG price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	177.4	-2.5%
Analysts Target Price	177.4	-2.5%
ValueRay Target Price	225.5	23.9%

Last update: 2025-10-04 03:50

ENSG Fundamental Data Overview

Market Cap USD = 10.12b (10.12b USD * 1.0 USD.USD)
P/E Trailing = 31.833
P/E Forward = 23.5849
P/S = 2.1931
P/B = 4.974
P/EG = 1.5727
Beta = 0.928
Revenue TTM = 4.61b USD
EBIT TTM = 431.7m USD
EBITDA TTM = 525.7m USD
Long Term Debt = 139.6m USD (from longTermDebt, last quarter)
Short Term Debt = 108.0m USD (from shortTermDebt, last quarter)
Debt = 2.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.68b USD (from netDebt column, last quarter)
Enterprise Value = 11.74b USD (10.12b + Debt 2.04b - CCE 418.4m)
Interest Coverage Ratio = 51.74 (Ebit TTM 431.7m / Interest Expense TTM 8.34m)
FCF Yield = 2.36% (FCF TTM 276.8m / Enterprise Value 11.74b)
FCF Margin = 6.00% (FCF TTM 276.8m / Revenue TTM 4.61b)
Net Margin = 6.99% (Net Income TTM 322.8m / Revenue TTM 4.61b)
Gross Margin = 15.88% ((Revenue TTM 4.61b - Cost of Revenue TTM 3.88b) / Revenue TTM)
Gross Margin QoQ = 16.19% (prev 16.04%)
Tobins Q-Ratio = 2.38 (Enterprise Value 11.74b / Total Assets 4.93b)
Interest Expense / Debt = 0.10% (Interest Expense 2.02m / Debt 2.04b)
Taxrate = 24.82% (27.9m / 112.4m)
NOPAT = 324.5m (EBIT 431.7m * (1 - 24.82%))
Current Ratio = 1.41 (Total Current Assets 1.07b / Total Current Liabilities 755.5m)
Debt / Equity = 1.01 (Debt 2.04b / totalStockholderEquity, last quarter 2.02b)
Debt / EBITDA = 3.19 (Net Debt 1.68b / EBITDA 525.7m)
Debt / FCF = 6.06 (Net Debt 1.68b / FCF TTM 276.8m)
Total Stockholder Equity = 1.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.55% (Net Income 322.8m / Total Assets 4.93b)
RoE = 17.15% (Net Income TTM 322.8m / Total Stockholder Equity 1.88b)
RoCE = 21.35% (EBIT 431.7m / Capital Employed (Equity 1.88b + L.T.Debt 139.6m))
RoIC = 16.01% (NOPAT 324.5m / Invested Capital 2.03b)
WACC = 7.86% (E(10.12b)/V(12.16b) * Re(9.43%) + D(2.04b)/V(12.16b) * Rd(0.10%) * (1-Tc(0.25)))
Discount Rate = 9.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.91%
[DCF Debug] Terminal Value 72.32% ; FCFE base≈246.7m ; Y1≈232.4m ; Y5≈218.8m
Fair Price DCF = 53.51 (DCF Value 3.09b / Shares Outstanding 57.7m; 5y FCF grow -7.47% → 3.0% )
EPS Correlation: -23.44 | EPS CAGR: -55.94% | SUE: -4.0 | # QB: 0
Revenue Correlation: 99.18 | Revenue CAGR: 18.49% | SUE: 1.57 | # QB: 1

Additional Sources for ENSG Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle